Sangamo ties up with a newcomer in the cell therapy field; LabCorp wins FDA authorization of latest Covid-19 test
→ A year after its launch, upstart cell conversion biotech Mogrify has inked a collaboration deal with Sangamo, which plans to put its own platform tech to work in developing allogeneic immunotherapeutic CAR-Tregs. Mogrify raised $20 million to put its cell tech to the test, looking to convert cells into other types of cells for use in a variety of therapeutic ways. It’s one of the latest advances in a field booted up by Shinya Yamanaka’s breakthrough work on stem cells 14 years ago. Mogrify gets an unspecified upfront and a high-profile partner in the alliance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.